Plasma Amino Acid Concentrations Predict Mortality in Patients with End-Stage Liver Disease

PLoS One. 2016 Jul 13;11(7):e0159205. doi: 10.1371/journal.pone.0159205. eCollection 2016.

Abstract

Background: The liver plays a key role in amino acid metabolism. In former studies, a ratio between branched-chain and aromatic amino acids (Fischer's ratio) revealed associations with hepatic encephalopathy. Furthermore, low concentrations of branched-chain amino acids were linked to sarcopenia in literature. Encephalopathy and sarcopenia are known to dramatically worsen the prognosis. Aim of this study was to investigate a complex panel of plasma amino acids in the context of mortality in patients with end-stage liver disease.

Methods: 166 patients evaluated for orthotopic liver transplantation were included. 19 amino acids were measured from citrated plasma samples using mass spectrometry. We performed survival analysis for plasma amino acid constellations and examined the relationship to established mortality predictors.

Results: 33/166 (19.9%) patients died during follow-up. Lower values of valine (p<0.001), Fischer's ratio (p<0.001) and valine to phenylalanine ratio (p<0.001) and higher values of phenylalanine (p<0.05) and tyrosine (p<0.05) were significantly associated with mortality. When divided in three groups, the tertiles discriminated cumulative survival for valine (p = 0.016), phenylalanine (p = 0.024) and in particular for valine to phenylalanine ratio (p = 0.003) and Fischer's ratio (p = 0.005). Parameters were also significantly correlated with MELD and MELD-Na score.

Conclusions: Amino acids in plasma are valuable biomarkers to determine increased risk of mortality in patients with end-stage liver disease. In particular, valine concentrations and constellations composed of branched-chain and aromatic amino acids were strongly associated with prognosis. Due to their pathophysiological importance, the identified amino acids could be used to examine individual dietary recommendations to serve as potential therapeutic targets.

MeSH terms

  • Amino Acids, Aromatic / blood*
  • Amino Acids, Aromatic / metabolism
  • Amino Acids, Branched-Chain / blood*
  • Amino Acids, Branched-Chain / metabolism
  • Biomarkers / blood
  • End Stage Liver Disease / blood*
  • End Stage Liver Disease / mortality
  • Female
  • Hepatic Encephalopathy / blood*
  • Hepatic Encephalopathy / mortality
  • Hepatic Encephalopathy / physiopathology
  • Humans
  • Liver Transplantation
  • Male
  • Mass Spectrometry
  • Middle Aged
  • Sarcopenia / blood*

Substances

  • Amino Acids, Aromatic
  • Amino Acids, Branched-Chain
  • Biomarkers

Grants and funding

This publication is supported by LIFE – Leipzig Research Center for Civilization Diseases, Universität Leipzig. LIFE is funded by means of the European Union, by the European Regional Development Fund (ERDF) and by means of the Free State of Saxony within the framework of the excellence initiative.